NASDAQ:BBNX - Nasdaq - US08659B1026 - Common Stock - Currency: USD
16.42
+0.02 (+0.12%)
The current stock price of BBNX is 16.42 USD. In the past month the price increased by 22.54%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 26.52 | 226.06B | ||
ISRG | INTUITIVE SURGICAL INC | 60.04 | 173.27B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.73 | 157.99B | ||
SYK | STRYKER CORP | 29.69 | 145.79B | ||
MDT | MEDTRONIC PLC | 16.3 | 114.85B | ||
IDXX | IDEXX LABORATORIES INC | 56.85 | 54.91B | ||
BDX | BECTON DICKINSON AND CO | 12.7 | 51.27B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.16 | 46.98B | ||
RMD | RESMED INC | 30.52 | 42.73B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.16 | 32.34B | ||
DXCM | DEXCOM INC | 44.85 | 29.90B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16 | 25.73B |
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 291 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
BETA BIONICS INC
11 Hughes
Irvine CALIFORNIA US
Employees: 291
Phone: 19494277785
The current stock price of BBNX is 16.42 USD. The price increased by 0.12% in the last trading session.
The exchange symbol of BETA BIONICS INC is BBNX and it is listed on the Nasdaq exchange.
BBNX stock is listed on the Nasdaq exchange.
15 analysts have analysed BBNX and the average price target is 24.03 USD. This implies a price increase of 46.33% is expected in the next year compared to the current price of 16.42. Check the BETA BIONICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BETA BIONICS INC (BBNX) has a market capitalization of 713.78M USD. This makes BBNX a Small Cap stock.
BETA BIONICS INC (BBNX) currently has 291 employees.
BETA BIONICS INC (BBNX) has a support level at 15.02 and a resistance level at 16.43. Check the full technical report for a detailed analysis of BBNX support and resistance levels.
The Revenue of BETA BIONICS INC (BBNX) is expected to grow by 30.6% in the next year. Check the estimates tab for more information on the BBNX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BBNX does not pay a dividend.
BETA BIONICS INC (BBNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
The outstanding short interest for BETA BIONICS INC (BBNX) is 12.53% of its float. Check the ownership tab for more information on the BBNX short interest.
ChartMill assigns a technical rating of 6 / 10 to BBNX.
ChartMill assigns a fundamental rating of 3 / 10 to BBNX. BBNX has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months BBNX reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -24.17% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -36.59% | ||
ROE | -72.04% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to BBNX. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -4.72% and a revenue growth 30.6% for BBNX